Swedish Oncology Pharmaceutical Company: Oasmia Pharmaceutical (OASM) (1988)

Oasmia Pharmaceutical AB (NASDAQ: OASM) was founded in 1988 and is headquartered in Uppsala, Sweden, with 57 full-time employees. It is a biopharmaceutical company focusing on innovative therapies for human and animal tumors.

Oasmia Pharmaceutical

Oasmia Pharmaceutical (OASM):

Oasmia Pharmaceutical Company mainly develops, produces, markets and sells human and veterinary oncology drugs in Sweden, focusing on manufacturing formulations based on cell inhibitors.

Oasmia Pharmaceutical’s approved products include Paclical / Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications.

In addition, Oasmia Pharmaceutical also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for breast and squamous cell carcinoma; and Doxophos Vet for lymphoma.

Oasmia Pharmaceutical (OASM) investment:

The company submitted the prospectus on 7/6/2015 and plans to land on Nasdaq on October 23, 2015. The issue price is US$4.1, the raised funds are US$23 million, and the stock code is OASM.

Notify of
Inline Feedbacks
View all Intels

China Stocks: Acorn International (ATV) (1998)

Medical technology leader: Medtronic (MDT) (1949)